We are live on ! Find out more
INFI

Infinity Pharmaceuticals, Inc.

Delisted

INFI was delisted on the 13th of September, 2023.

98 hedge funds and large institutions have $598M invested in Infinity Pharmaceuticals, Inc. in 2014 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 37 increasing their positions, 32 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

16% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 32

5% more capital invested

Capital invested by funds: $570M → $598M (+$28.2M)

0% more funds holding

Funds holding: 9898 (0)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 13

57% less call options, than puts

Call options by funds: $4.84M | Put options by funds: $11.2M

Holders
98
Holders Change
Holders Change %
0%
% of All Funds
2.82%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
13
Increased
37
Reduced
32
Closed
13
Calls
$4.84M
Puts
$11.2M
Net Calls
-$6.38M
Net Calls Change
-$1.69M
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$63.6M +$4.91M +471,575 +10%
O
2
OrbiMed
New York
$60.3M
DM
3
Deerfield Management
New York
$46.8M -$8.01M -769,189 -17%
Point72 Asset Management
4
Point72 Asset Management
Connecticut
$43.5M +$35.5M +3,410,978 New
Goldman Sachs
5
Goldman Sachs
New York
$43.2M -$2.91M -279,105 -8%
Vanguard Group
6
Vanguard Group
Pennsylvania
$34.5M +$493K +47,288 +2%
BFA
7
BlackRock Fund Advisors
California
$28.8M +$3.76M +360,491 +19%
State Street
8
State Street
Massachusetts
$25.1M -$1.29M -124,055 -6%
Wellington Management Group
9
Wellington Management Group
Massachusetts
$22.8M +$2.18M +209,626 +13%
BB
10
BB Biotech
Switzerland
$19.2M +$2.14M +205,000 +16%
BC
11
Broadfin Capital
New York
$18.3M +$1.17M +112,484 +8%
BIT
12
BlackRock Institutional Trust
California
$17.5M +$139K +13,355 +1%
GPP
13
Great Point Partners
Connecticut
$12.2M +$4.77M +458,200 +92%
HM
14
HealthCor Management
New York
$11.8M -$1.32M -126,400 -12%
Norges Bank
15
Norges Bank
Norway
$8.75M +$3.58M +343,291 +100%
TCM
16
Tekla Capital Management
Massachusetts
$8.67M +$3.45M +330,847 +95%
BBA
17
Baker Bros. Advisors
New York
$7.95M
T. Rowe Price Associates
18
T. Rowe Price Associates
Maryland
$7.93M +$65.6K +6,300 +1%
Adage Capital Partners
19
Adage Capital Partners
Massachusetts
$7.64M -$1.04M -100,000 -14%
Northern Trust
20
Northern Trust
Illinois
$7.25M -$418K -40,144 -7%
BA
21
BlackRock Advisors
Delaware
$6.5M -$54.4K -5,218 -1%
Millennium Management
22
Millennium Management
New York
$6M -$114K -10,976 -2%
Franklin Resources
23
Franklin Resources
California
$5.68M
Ameriprise
24
Ameriprise
Minnesota
$5.42M -$3.67M -352,355 -45%
Dimensional Fund Advisors
25
Dimensional Fund Advisors
Texas
$5.17M +$329K +31,573 +8%

INFI Hedge Fund Activity: Q2 2014 in Review

98 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in Infinity Pharmaceuticals, Inc. (INFI) for Q2 2014, worth a combined $598M — up 4.9% from $570M a quarter earlier.

Fund positioning in INFI was balanced in Q2 2014: 13 funds opened new positions, 13 closed out, 37 added to existing stakes and 32 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $4.91M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $15M sold.

  • 98 institutional investors held Infinity Pharmaceuticals, Inc. (INFI) as of Q2 2014, unchanged from Q1 2014.
  • Funds reported $598M of Infinity Pharmaceuticals, Inc. stock for Q2 2014, up 4.9% quarter-over-quarter.
  • 13 funds opened new Infinity Pharmaceuticals, Inc. positions in Q2 2014 and 13 closed out, a net change of 0 holders.
  • The largest Infinity Pharmaceuticals, Inc. buyer in Q2 2014 was Fidelity Investments, an estimated $4.91M added.
  • The largest Infinity Pharmaceuticals, Inc. seller in Q2 2014 was Consonance Capital Management, an estimated $15M sold.

Based on aggregated 13F filings for Q2 2014.